title: Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
authors.affiliation: University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington; Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain; Biomedical Research Center in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain. Electronic address: jdeleon@uky.edu.
authors.forename: Jose
authors.initials: J
authors.lastname: de Leon
mesh_terms: D000069445:Atomoxetine Hydrochloride / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D010597:Pharmacogenetics; D017410:Practice Guidelines as Topic; D057285:Precision Medicine; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000069445:Atomoxetine Hydrochloride; D019389:Cytochrome P-450 CYP2D6